Truist Securities maintains Buy rating on Axsome Therapeutics, $285 price target

Truist Securities maintained their Buy rating on Axsome Therapeutics's stock with a price target of $285.00.The price target implies an upside of 40.3% from the Sep 22 close of $203.10.Key takeaways from the analyst noteStrong Revenue Growth and Market Penetration: Axsome Therapeutics has demonstra…